肺癌组织中KAI1/CD82和整合素α5的表达及意义

The Expression and Significance of KAI1/CD82 and Integrin α 5in Lung Cancer

目的:研究KAI1/CD82和整合素α5在肺癌组织中的表达及其与临床病理特征的关系。方法:应用免疫组织化学方法检测110例肺癌组织中KAI1/CD82及整合素α5的表达情况。结果:KAI1/CD82在肺癌中的表达阳性率为37.3%,α5的表达阳性率为44.5%。二者的表达水平在淋巴结转移方面差异有显著性意义(r>0,P<0.05)。KAI1/CD82的表达在TNM分期方面差异亦呈显著性意义(r>0,P<0.05)。二者的表达水平与年龄、性别、病变部位、肿瘤大小、分化程度及病理类型无关(P>0.05)。结论:KAI1/CD82和整合素α5与淋巴结转移相关,二者可作为判定肺癌浸润和转移的指标。

Objective: To investigate the expression of KAI1/CD82 and integrin α 5 in lung cancer and its relationship with clinical features. Methods: The expression of KAI1/CD82 and integrin α 5 in 110 lung cancers was detected with immunohistochemistry. Results: The positive expression rate of KAI1/CD82 and integrin α 5 in lung cancer was 37.3% and 44.5% respectively. Significance difference was revealed concerning the metastatic nodes (r>0, P<0.05). Furthermore, the difference was remarkable with respect to the expression of KAI1/CD82 on TNM staging (r>0, P<0.05). There was not strong evidence to support the correlation on the expression of KAI1/CD82 and integrin α 5 with age, sex, tumor location, tumor size, cell differentiation and histology (P>0.05). Conclusion: KAI1/CD82 and integrin α 5 correlates with nodal metastasis. Both of them could be used as indexes to evaluate the invasion and metastasis of lung carcinoma.